Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.43
−$0.26 · -5.54%
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Previous close
$4.43
−$0.26 · -5.54%
Regular session · ET · Market data may be delayed.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Day range
Current $4.43
52-week range
Current $4.43
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
60
Fair Value
Sentiment
44
Mixed
Risk
63
High Risk
Momentum
41
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Day range
Current $4.43
52-week range
Current $4.43
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 5.76M USD | 11.9M USD | 12.71M USD | 14.65M USD | 32.04M USD |
| Selling, general, and administrative | 9.34M USD | 9.95M USD | 10.41M USD | 10.58M USD | 13.33M USD |
| Operating expenses | 15.1M USD | 21.85M USD | 23.12M USD | 25.23M USD | 45.37M USD |
| Interest income | 948.12K USD | 1.27M USD | 1.44M USD | 556.95K USD | 16.52K USD |
| Interest expense | — | 4.56M USD | 8.28M USD | 7.41M USD | 6.33M USD |
| Depreciation and amortization | 5.44K USD | 22.47K USD | 30.98K USD | 8.51K USD | 101.79K USD |
| Operating income | −15.1M USD | −21.85M USD | −23.12M USD | −25.23M USD | −45.37M USD |
| Net income | −293.42M USD | 1.44M USD | −30.01M USD | −32.11M USD | −49.91M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.00
125.73% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 21, 2022 | 1:8 | — | — |
Effective Jun 21, 2022
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.25M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM2.87M0.00%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF2.12M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO980.07K0.01%14.58B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO758.88K0.00%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC520.33K0.04%1.47B USD0.60%$196.25+0.69%
iShares Russell 2000 Value ETFIWN411.1K0.00%14.47B USD0.24%$224.62+0.40%
Invesco NASDAQ Future Gen 200 ETFQQQS101K0.44%22.81M USD0.20%$44.7464+1.01%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Russell 2000 Value ETFIWNInvesco NASDAQ Future Gen 200 ETFQQQSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
